FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385703411> ?p ?o ?g. }

• W4385703411 endingPage "e951300c" @default.
• W4385703411 startingPage "e951300c" @default.
• W4385703411 abstract "Topic: 13. Myeloma and other monoclonal gammopathies - Biology & Translational Research Background: Multiple myeloma (MM) is an incurable hematological malignancy of monoclonal proliferation of plasma cells in the bone marrow. According to NCCN guidelines, the Durie-Salmon Staging System (DS staging) and International Staging System (ISS staging) were used for prognostic assessment and risk stratification of MM. However, this risk system also has limited accuracy in survival prediction and assigns a large fraction of the patients to an intermediate-risk group whose outcomes are largely uncertain. Proteasome inhibitor (bortezomib) is the backbone of patients’ standard therapy with a higher response ratio and prolonged survival. However, some patients will ultimately relapse and progress. Metabolism reprogramming is now recognized as a hallmark of cancer. Lactate, a metabolite of the glycolytic pathway, was associated with the severity of critical illness and participated in the tumorigenesis and development of tumors. In hematological malignancies, lactate acidosis indicates an inferior clinical prognosis for lymphoma and myeloma. However, there was no specific research on lactate utilized as a biomarker, promoting myeloma evolution and resistance to chemotherapy, and its mechanisms in multiple myeloma. Aims: To explore the role and clinical significance of lactate as a biomarker in MM, and to investigate the function and mechanism of Lac in promoting the proliferation and reducing the sensitivity of BTZ in MM. Methods: Take targeted energy metabonomics to explore differences in metabolism substances in peripheral blood and bone marrow in MM. Expanding peripheral blood samples validated the elevated lactate in MM, investigated the correlation of lactate with clinical characteristics, and assessed the value of lactate as a biomarker of multiple myeloma. The myeloma cells were cultured in vitro and utilized CCK-8 to detect cell viability after being treated with Lac in different concentrations and times. Applied BTZ or combined Lac to treat with cells, explored apoptosis and cell cycle changes by flow cytometry, and detected the apoptosis and cycle-related proteins changes by Western blot. After applying BTZ or combined Lac to treat with cells, use western blot to detect the changes in the NF-kappa B pathway proteins. Results: Targeted energy metabolomics showed MM’s cyclic AMP, lactate, α-ketoglutarate, glucose-6-phosphate, and malic acid were significantly increased compared with control subjects. Lactate of the peripheral blood in MM is significantly higher than in normal subjects. The lactate was positively correlated with the DS stage, ISS stage, and the ratio of involved/unaffected free light chains in hematuria. Overmore, the patients with more elevated lactate have unsatisfactory responses. Vitro proliferation, apoptosis, and cell cycle in myeloma cells showed that lower dose Lac could promote the proliferation and the transformation of cell cycle G0/G1 to S, but not affect the apoptosis. Western blot results also confirmed the corresponding changes in cell cycle-related proteins. The combined Lac decreased the sensitivity of BTZ and antagonized the BTZ-induced apoptosis and G2/M cycle arrest in cells. BTZ decreased the protein levels of NFKB2 and RelB, while Lac increased them. The combined Lac could partially recover the reduction in NFKB2 and RelB protein caused by BTZ. Summary/Conclusion: Metabolic changes are important for MM tumor cell proliferation and treatment response. Lactate could be used as a biomarker for MM and as a therapeutic target to overcome the chemotherapy resistance of BTZ.Keywords: Multiple myeloma, Drug resistance, Bortezomib" @default.
• W4385703411 created "2023-08-10" @default.
• W4385703411 creator A5003984719 @default.
• W4385703411 creator A5008044294 @default.
• W4385703411 creator A5008759729 @default.
• W4385703411 creator A5025382217 @default.
• W4385703411 creator A5031976013 @default.
• W4385703411 creator A5037492794 @default.
• W4385703411 creator A5056061504 @default.
• W4385703411 creator A5070538645 @default.
• W4385703411 creator A5073298096 @default.
• W4385703411 date "2023-08-01" @default.
• W4385703411 modified "2023-09-27" @default.
• W4385703411 title "PB2079: LACTATE DECREASES BORTEZOMIB SENSITIVITY AND PREDICTS POOR CLINICAL OUTCOMES OF MULTIPLE MYELOMA" @default.
• W4385703411 doi "https://doi.org/10.1097/01.hs9.0000975112.95130.0c" @default.
• W4385703411 hasPublicationYear "2023" @default.
• W4385703411 type Work @default.
• W4385703411 citedByCount "0" @default.
• W4385703411 crossrefType "journal-article" @default.
• W4385703411 hasAuthorship W4385703411A5003984719 @default.
• W4385703411 hasAuthorship W4385703411A5008044294 @default.
• W4385703411 hasAuthorship W4385703411A5008759729 @default.
• W4385703411 hasAuthorship W4385703411A5025382217 @default.
• W4385703411 hasAuthorship W4385703411A5031976013 @default.
• W4385703411 hasAuthorship W4385703411A5037492794 @default.
• W4385703411 hasAuthorship W4385703411A5056061504 @default.
• W4385703411 hasAuthorship W4385703411A5070538645 @default.
• W4385703411 hasAuthorship W4385703411A5073298096 @default.
• W4385703411 hasBestOaLocation W43857034111 @default.
• W4385703411 hasConcept C126322002 @default.
• W4385703411 hasConcept C143998085 @default.
• W4385703411 hasConcept C159654299 @default.
• W4385703411 hasConcept C163864487 @default.
• W4385703411 hasConcept C203014093 @default.
• W4385703411 hasConcept C2776364478 @default.
• W4385703411 hasConcept C2777250017 @default.
• W4385703411 hasConcept C2777478702 @default.
• W4385703411 hasConcept C2780007613 @default.
• W4385703411 hasConcept C2781197716 @default.
• W4385703411 hasConcept C542903549 @default.
• W4385703411 hasConcept C55493867 @default.
• W4385703411 hasConcept C71924100 @default.
• W4385703411 hasConcept C86803240 @default.
• W4385703411 hasConceptScore W4385703411C126322002 @default.
• W4385703411 hasConceptScore W4385703411C143998085 @default.
• W4385703411 hasConceptScore W4385703411C159654299 @default.
• W4385703411 hasConceptScore W4385703411C163864487 @default.
• W4385703411 hasConceptScore W4385703411C203014093 @default.
• W4385703411 hasConceptScore W4385703411C2776364478 @default.
• W4385703411 hasConceptScore W4385703411C2777250017 @default.
• W4385703411 hasConceptScore W4385703411C2777478702 @default.
• W4385703411 hasConceptScore W4385703411C2780007613 @default.
• W4385703411 hasConceptScore W4385703411C2781197716 @default.
• W4385703411 hasConceptScore W4385703411C542903549 @default.
• W4385703411 hasConceptScore W4385703411C55493867 @default.
• W4385703411 hasConceptScore W4385703411C71924100 @default.
• W4385703411 hasConceptScore W4385703411C86803240 @default.
• W4385703411 hasIssue "S3" @default.
• W4385703411 hasLocation W43857034111 @default.
• W4385703411 hasLocation W43857034112 @default.
• W4385703411 hasOpenAccess W4385703411 @default.
• W4385703411 hasPrimaryLocation W43857034111 @default.
• W4385703411 hasRelatedWork W115137046 @default.
• W4385703411 hasRelatedWork W1984437179 @default.
• W4385703411 hasRelatedWork W2020472919 @default.
• W4385703411 hasRelatedWork W2089743544 @default.
• W4385703411 hasRelatedWork W2147423551 @default.
• W4385703411 hasRelatedWork W2333239088 @default.
• W4385703411 hasRelatedWork W2579731866 @default.
• W4385703411 hasRelatedWork W2784211356 @default.
• W4385703411 hasRelatedWork W2953107159 @default.
• W4385703411 hasRelatedWork W3185445157 @default.
• W4385703411 hasVolume "7" @default.
• W4385703411 isParatext "false" @default.
• W4385703411 isRetracted "false" @default.
• W4385703411 workType "article" @default.